

Clascoterone cream safe, effective for acne treatment

April 23 2020



(HealthDay)—Clascoterone cream, 1 percent, appears to be safe and

effective for the treatment of acne, according to a study published online April 22 in *JAMA Dermatology*.

Adelaide Hebert, M.D., from the University of Texas Health Science Center in Houston, and colleagues assessed the safety and efficacy of clascoterone [cream](#), 1 percent, a novel topical androgen receptor inhibitor, in two phase 3 [clinical trials](#) (including a total 1,440 patients) in which patients were randomly assigned to clascoterone cream, 1 percent, or a [vehicle](#) cream.

The researchers found that at week 12, the treatment success rates with clascoterone cream were 18.4 and 20.3 percent versus 9 and 6.5 percent with vehicle creams, respectively. In both intervention groups at week 12, there was a significant reduction in absolute noninflammatory lesions from baseline to -19.4 versus -13 and -10.8 with the vehicle cream, respectively. Similarly, there was a reduction in [inflammatory lesions](#) from baseline in the two intervention groups of -19.3 and -20 versus -15.5 and -12.6 with vehicle cream, respectively. The predominant adverse reaction was trace or mild erythema, but rates were low.

"Clascoterone cream, 1 percent, is under consideration as a first-in-class therapeutic agent for acne treatment, potentially providing an alternative to antibiotics and/or offering an adjunct treatment to existing combination acne therapies, including retinoids," the authors write.

Several authors disclosed financial ties to [pharmaceutical companies](#), including Cassiopea, which manufactures clascoterone and funded the study.

More information: [Abstract/Full Text](#)
[Editorial](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Clascoterone cream safe, effective for acne treatment (2020, April 23) retrieved 24 December 2023 from <https://medicalxpress.com/news/2020-04-clascoterone-cream-safe-effective-acne.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.